In this edition
- Menopause Essentials Update
- Menopausal Hormone Therapy (MHT) discontinuation and shortages March 2025
- AMS Webinar: After the IMS World Congress 2024 - Your queries, dilemmas and tricky questions answered archive
- AMS Congress 2025 - Fremantle WA
- Health Services Research Grants 2025
Health Professionals - join AMS for Members-only content
- The Menopause Society’s 2025 Annual Meeting
- European Menopause and Andropause Society (EMAS) Newsletter
In this edition
AMS News
This Menopause Essentials Update is designed as a wrap up of evidence-based management options for menopause and midlife health. Starting with structuring the initial consultation in the most effective way and finishing with a discussion of complex cases, the Menopause Essentials Update includes the latest on hormonal and non-hormonal options and up to date best-practice risk management recommendations across the full spectrum of menopause medicine.
Speakers include:Dr Amie Hanlon,Dr Christina Jang,Dr Samantha Kerr, and Dr Hannah Farquhar.
9.00 am
|
The menopause consultation: Dr Samantha Kerr
|
9.40 am
|
Prescribing menopausal hormone therapy: Dr Hannah Farquhar
|
10.20am
|
Morning Tea
|
10.50am
|
Non-hormonal therapies: Dr Christina Jang
|
11.30 am
|
Management of bleeding on and off MHT: Dr Amie Hanlon
|
12.10 am
|
Panel discussion (all speakers): Cases | Q+A
|
CPD Points available:
The Menopause Essentials Update in Brisbane will run for 4 hours. It has been approved by ACRRM as 2.5hrs EA and 1hr RP (Activity number 36507)
CPD approval pending for RACGP and RANZCOG.
AMS Webinar: After the IMS World Congress 2024 - Your queries, dilemmas and tricky questions answered
The AMS Webinar is now available for review.
If you did not have the opportunity to attend the webinar the archive version (also with CPD points) is now available on
Menopausal Hormone Therapy (MHT) discontinuation and shortages April 2025
Australia
Patch Shortages
There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.
Oestradiol patches
|
Availability and expected supply due
|
Alternative supply under Section 19A
|
Dose
|
Estradot
|
Estraderm
|
Estramon
|
Estradiol Transdermal System
|
25mcg
|
Unavailable - 31 Dec 2025
|
Limited - 30 June 2025
|
Available
|
|
37.5mcg
|
Unavailable - 30 Jun 2025
|
|
Available
|
Available
|
50 mcg
|
Unavailable - 31 Dec 2025
|
Limited - 30 June 2025
|
Available
|
Unavailable
|
75 mcg
|
Unavailable - 31 Dec 2025
|
Limited - 30 June 2025
|
Available
|
Unavailable
|
100mcg
|
Unavailable - 31 Dec 2025
|
Limited - 30 June 2025
|
Available
|
Available
|
Combined patches
Dose
|
Estalis Sequi
|
Estalis Conti
|
50/140
|
Unavailable – 30 June 2025
|
Unavailable – 30 June 2025
|
50/250
|
Unavailable – 30 June 2025
|
Limited – 30 June 2025
|
All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.
The provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.
New Zealand
As at 14th April 2025, patch availability is provided below.
Dose
|
Estradot
|
Viatris
|
Estraderm MX
|
25mcg
|
Limited
|
Available
|
Available
|
50mcg
|
Limited
|
Available
|
|
75mcg
|
Limited
|
Available
|
|
100mcg
|
Limited
|
Available
|
|
More information can be found
The provides a guideline to approximately equivalent doses of the different MHT/HRT products in New Zealand.
AMS Congress 2025 - Fremantle WA
Registration now open
Health Services Research Grants 2025
The HCF Research Foundation Health Services Research Grants 2025 program is now open for expressions of interest.
The 15th annual call for research projects will deliver funding to the research community from 1 January 2026.
This year's Grant Round will involve an Expression of Interest (EOI) stage prior to full Application.
The foundation invites an expression of interest if your health services research project addresses one of the following areas:
- Structural and employment design approaches that improve the satisfaction and retention of the healthcare workforce leading to improved care continuity, patient safety and health outcomes and supporting the sustainability of the health care system.
- Evaluation of acute hospital avoidance programs and approaches to address frequent and/or unnecessary emergency presentations.
- Implementation strategies for pain management models of care that reduce the risk of pain chronicity and opioid overuse and addiction.
More information can be found
Expressions of interest close 5pm on Monday 19th May 2025 (AEST).
If you have any questions in relation to the application process, please read through the application guidelines. If you require further clarification, please contact the foundation by email: hcffoundation@hcf.com.au.
Health Professionals - join AMS for Members-only content
The Menopause Society’s 2025 Annual Meeting
European Menopause and Andropause Society (EMAS) NewsletterAMS is an affiliate of EMAS.See latest copy.